Alnylam Revenue Per Share from 2010 to 2025
| ALNY Stock | USD 280.96 9.74 3.35% |
Revenue Per Share | First Reported 2010-12-31 | Previous Quarter 17.48380901 | Current Value 18.36 | Quarterly Volatility 6.37938439 |
Check Alnylam Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alnylam Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 59.5 M, Interest Expense of 149 M or Other Operating Expenses of 2.5 B, as well as many indicators such as Price To Sales Ratio of 12.79, Dividend Yield of 0.0 or PTB Ratio of 474. Alnylam financial statements analysis is a perfect complement when working with Alnylam Pharmaceuticals Valuation or Volatility modules.
Alnylam | Revenue Per Share |
Latest Alnylam Pharmaceuticals' Revenue Per Share Growth Pattern
Below is the plot of the Revenue Per Share of Alnylam Pharmaceuticals over the last few years. It is the amount of revenue generated by a company per share of stock, calculated by dividing total revenue by the average number of shares outstanding. Alnylam Pharmaceuticals' Revenue Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Alnylam Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 17.612 | 10 Years Trend |
|
Revenue Per Share |
| Timeline |
Alnylam Revenue Per Share Regression Statistics
| Arithmetic Mean | 5.01 | |
| Geometric Mean | 2.08 | |
| Coefficient Of Variation | 127.39 | |
| Mean Deviation | 5.14 | |
| Median | 1.95 | |
| Standard Deviation | 6.38 | |
| Sample Variance | 40.70 | |
| Range | 18.1733 | |
| R-Value | 0.83 | |
| Mean Square Error | 13.35 | |
| R-Squared | 0.69 | |
| Significance | 0.000062 | |
| Slope | 1.12 | |
| Total Sum of Squares | 610.45 |
Alnylam Revenue Per Share History
About Alnylam Pharmaceuticals Financial Statements
Alnylam Pharmaceuticals investors use historical fundamental indicators, such as Alnylam Pharmaceuticals' Revenue Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Alnylam Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Revenue Per Share | 17.48 | 18.36 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Alnylam Stock Analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.